Immunic Therapeutics

Immunic Therapeutics is a dynamic biotechnology company focused on the discovery and development of innovative small molecule therapies. With a commitment to addressing chronic inflammatory and autoimmune diseases, Immunic Therapeutics is dedicated to advancing patient care through cutting-edge research and clinical development. The company's strategic approach and focus on orally administered treatments position it as a key player in the biotechnology sector.

Operating from its primary location at 1200 Avenue of the Americas, Suite 200, New York City, New York 10036, US, and with additional facilities at Lochhamer Schlag 21, Gräfelfing, Bayern 82166, DE, Immunic Therapeutics is expanding its capabilities and broadening its impact on the biotechnology landscape. By leveraging its expertise in molecular therapies, Immunic Therapeutics aims to develop novel treatments that offer improved outcomes for patients suffering from chronic conditions.

Immunic Therapeutics is poised for continued growth and success in the biotechnology industry. The company's commitment to innovation and patient-centric solutions drives its mission to make a significant difference in healthcare. We invite the management of Immunic Therapeutics to create a customized and exclusive company showcase and product listing on our platform, further enhancing their visibility and commercial development.